Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S100A4 | P26447 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.38 |
| ▸ | HSD11B2 | P80365 | 4/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4010767 | 1.00 | S100A4 (0.41) | S100A4KMT2AMEN1BTKHSD11B1 | |
| SCHEMBL4011662 | 0.94 | KMT2A (0.42) | S100A4KMT2AMEN1BTKHSD11B1 | |
| SCHEMBL3999588 | 0.94 | KMT2A (0.42) | S100A4KMT2AMEN1BTKHSD11B1 | |
| SCHEMBL4011713 | 0.91 | SYK (0.39) | S100A4KMT2AMEN1HSD11B1HSD11B2 | |
| SCHEMBL4004297 | 0.90 | HSD11B1 (0.40) | S100A4KMT2AMEN1HSD11B1HSD11B2 | |
| SCHEMBL4152408 | 0.89 | HSD11B1 (0.44) | BTKHSD11B1 | |
| SCHEMBL4002517 | 0.89 | KMT2A (0.47) | S100A4KMT2AMEN1BTKHSD11B1 | |
| SCHEMBL4002511 | 0.89 | KMT2A (0.47) | S100A4KMT2AMEN1BTKHSD11B1 | |
| SCHEMBL4143208 | 0.89 | HSD11B1 (0.41) | KMT2AHSD11B1HSD11B2 | |
| SCHEMBL4003550 | 0.88 | SYK (0.40) | KMT2AMEN1HSD11B1HSD11B2SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101080226-A | Amido compounds and their use as pharmaceuticals | INCYTE CORP (US) | 2007-11-28 | — | — | CN | claimed |
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-08 | — | — | US | claimed |
| EP-1778229-A4 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| CN-101080226-A | Amido compounds and their use as pharmaceuticals | INCYTE CORP (US) | 2007-11-28 | — | — | CN | disclosed |
| EP-1778229-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-05-02 | — | — | EP | disclosed |
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION | 2006-06-08 | — | — | US | disclosed |
| WO-2006020598-A2 | AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122197-A1 | Amido compounds and their use as pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | S100A4 4828/4885KMT2A 3418/4885MEN1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.